TY - JOUR
T1 - Brain natriuretic peptide is present in the human amniotic fluid and is secreted from amnion cells
AU - Itoh, Hiroaki
AU - Sagawa, Norimasa
AU - Hasegawa, Masaaki
AU - Okagaki, Atsuhiko
AU - Inamori, Kumiko
AU - Ihara, Yoshiyuki
AU - Mori, Takahide
AU - Ogawa, Yoshihiro
AU - Suga, Shin Ichi
AU - Mukoyama, Masashi
AU - Nakao, Kazuwa
AU - Imura, Hiroo
PY - 1993/4
Y1 - 1993/4
N2 - The presence and biochemical characteristics of human brain natriuretic peptide (hBNP) in the amniotic fluid at various gestational ages were investigated. The hBNP-like immunoreactivity (hBNP-LI) levels in amniotic fluid, determined by RIA, were 118.7 ± 57.6 pmol/L (mean ± SEM; n = 5) and 107.7 ± 8.7 pmol/L (n = 9) in the first and second trimesters of pregnancy, respectively; it was significantly decreased to 28.4 ± 5.1 pmol/L (n = 9) in the third trimester. However, human atrial natriuretic peptide-like immunoreactivity (hANP-LI) was not detected (< 0.3 pmol/L) in any of these samples. Northern blot analysis demonstrated hBNP mRNA in human amnion tissue. Moreover, cultured amnion cells secreted a significant amount of hBNP-LI (100-200 fmol/106 cells/day), but not hANP-LI, into the culture medium. The synthesis of hBNP in cultured amnion cells was further confirmed using the polymerase chain reaction. High performance gel permeation chromatography of hBNP-LI extracted from human amniotic fluid and the culture medium of amnion cells revealed that the predominant molecular form of hBNP-LI in both samples was the hBNP precursor, with an approximate mol wt of 12 kilodaltons. These findings indicate that hBNP is present in the human amniotic fluid, and that amnion cells synthesize hBNP and secrete it into the amniotic cavity.
AB - The presence and biochemical characteristics of human brain natriuretic peptide (hBNP) in the amniotic fluid at various gestational ages were investigated. The hBNP-like immunoreactivity (hBNP-LI) levels in amniotic fluid, determined by RIA, were 118.7 ± 57.6 pmol/L (mean ± SEM; n = 5) and 107.7 ± 8.7 pmol/L (n = 9) in the first and second trimesters of pregnancy, respectively; it was significantly decreased to 28.4 ± 5.1 pmol/L (n = 9) in the third trimester. However, human atrial natriuretic peptide-like immunoreactivity (hANP-LI) was not detected (< 0.3 pmol/L) in any of these samples. Northern blot analysis demonstrated hBNP mRNA in human amnion tissue. Moreover, cultured amnion cells secreted a significant amount of hBNP-LI (100-200 fmol/106 cells/day), but not hANP-LI, into the culture medium. The synthesis of hBNP in cultured amnion cells was further confirmed using the polymerase chain reaction. High performance gel permeation chromatography of hBNP-LI extracted from human amniotic fluid and the culture medium of amnion cells revealed that the predominant molecular form of hBNP-LI in both samples was the hBNP precursor, with an approximate mol wt of 12 kilodaltons. These findings indicate that hBNP is present in the human amniotic fluid, and that amnion cells synthesize hBNP and secrete it into the amniotic cavity.
UR - http://www.scopus.com/inward/record.url?scp=0027480374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027480374&partnerID=8YFLogxK
U2 - 10.1210/jcem.76.4.8473404
DO - 10.1210/jcem.76.4.8473404
M3 - Article
C2 - 8473404
AN - SCOPUS:0027480374
SN - 0021-972X
VL - 76
SP - 907
EP - 911
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 4
ER -